comparemela.com

Latest Breaking News On - Stevenk galson - Page 1 : comparemela.com

Oracle Investment Management Inc. Sells 19,964 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Oracle Investment Management Inc. reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 535,558 shares of the biotechnology company’s stock after selling 19,964 shares during the period. […]

Alang-levin
Stevenk-galson
Exchange-commission
Securities-exchange-commission
News-ratings-for-biocryst-pharmaceuticals-daily
Quarter-for-biocryst-pharmaceuticals
Deerfield-management-companylp-series
Vanguard-group-inc
Nasdaq
Needham-company
Oracle-investment-management-inc

Avoro Capital Advisors LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Avoro Capital Advisors LLC lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,050,000 shares of the biotechnology company’s stock after purchasing an additional 1,500,000 shares during […]

Recursos-ltda
Stevenk-galson
Nancyj-hutson
Quarter-for-biocryst-pharmaceuticals
Exchange-commission
Nasdaq
Pinnacle-wealth-planning-services-inc
Avoro-capital-advisors
Biocryst-pharmaceuticals-inc
News-ratings-for-biocryst-pharmaceuticals-daily
Biocryst-pharmaceuticals
Securities-exchange-commission

Avoro Capital Advisors LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Avoro Capital Advisors LLC lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,050,000 shares of the biotechnology company’s stock after purchasing an additional 1,500,000 shares during […]

Recursos-ltda
Nancyj-hutson
Stevenk-galson
Biocryst-pharmaceuticals
Biocryst-pharmaceuticals-stock-performance
Securities-exchange-commission
Biocryst-pharmaceuticals-company-profile
Needham-company
Capstone-investment-advisors
Tower-research-capital
Quarter-for-biocryst-pharmaceuticals
Pinnacle-wealth-planning-services-inc

Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $14.00

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last […]

Nancyj-hutson
Stevenk-galson
Insider-transactions-at-biocryst-pharmaceuticals
Institutional-trading-of-biocryst-pharmaceuticals
Tower-research-capital
Biocryst-pharmaceuticals-company-profile
Biocryst-pharmaceuticals
Biocryst-pharmaceuticals-stock-down
Biocryst-pharmaceuticals-inc
Fifth-third-bancorp
Analyst-recommendations-for-biocryst-pharmaceuticals

The Impact of COVID-19 on Clinical Research in the Life Sciences Industry: Is there a Silver Lining? | Nexsen Pruet, PLLC

Clinical research is one of the foundations of the Life Sciences industry as it involves the scientific investigation and treatment of diseases and other medical conditions in order to.

Nexsen-pruet
Philip-ball
Mark-clements
Matthew-roberts
Stevenk-galson
Gregory-simon
Nataliya-volohov
Esther-krofah
Robertm-califf
Rakel-meir
Digital-technology

vimarsana © 2020. All Rights Reserved.